Cargando…
Anti-oxidative Amino Acid L-ergothioneine Modulates the Tumor Microenvironment to Facilitate Adjuvant Vaccine Immunotherapy
Cancer vaccines consist of a tumor-associated antigen (TAA) and adjuvant. These vaccines induce and activate proliferation of TAA-specific cytotoxic T lymphocytes (CTLs), suppressing tumor growth. The therapeutic efficacy of TAA-specific CTLs depends on the properties of tumor microenvironment. The...
Autores principales: | Yoshida, Sumito, Shime, Hiroaki, Matsumoto, Misako, Kasahara, Masanori, Seya, Tsukasa |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6458301/ https://www.ncbi.nlm.nih.gov/pubmed/31019508 http://dx.doi.org/10.3389/fimmu.2019.00671 |
Ejemplares similares
-
The Anti-Oxidant Ergothioneine Augments the Immunomodulatory Function of TLR Agonists by Direct Action on Macrophages
por: Yoshida, Sumito, et al.
Publicado: (2017) -
Vaccine immunotherapy with ARNAX induces tumor‐specific memory T cells and durable anti‐tumor immunity in mouse models
por: Takeda, Yohei, et al.
Publicado: (2018) -
Toll-like receptor 2 ligand and interferon-γ suppress anti-tumor T cell responses by enhancing the immunosuppressive activity of monocytic myeloid-derived suppressor cells
por: Shime, Hiroaki, et al.
Publicado: (2017) -
Adjuvant immunotherapy for cancer: both dendritic cell-priming and check-point inhibitor blockade are required for immunotherapy
por: SEYA, Tsukasa, et al.
Publicado: (2018) -
Adjuvant for vaccine immunotherapy of cancer – focusing on Toll‐like receptor 2 and 3 agonists for safely enhancing antitumor immunity
por: Seya, Tsukasa, et al.
Publicado: (2015)